Prot #GSK 204862: TANGO: A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority Study Evaluating the Efficacy, safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed